APGN(Delisted)
ApexigenยทNASDAQ
--
--(--)
APGN Profile
Apexigen, Inc.
A clinical-stage biopharmaceutical company that developing a new generation of antibody therapeutics for oncology to combat and eradicate cancer
75 Shoreway Road, Suite C, San Carlos, CA 94070
--
Apexigen, Inc., was incorporated in Delaware in 2010. The company is a clinical-stage biopharmaceutical company focused on the development of innovative antibody therapies for the treatment of cancer, with an emphasis on immuno-oncology. The company has established a diversified pipeline of wholly-owned and cooperative assets using its proprietary APXiMAB antibody discovery platform. The company's main asset, sotigalimab, is a potential best-in-class and first-in-class CD40 agonist with unique epitope specificity and Fc receptor involvement for optimal therapeutic outcomes.
